Abstract
Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2 h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosuppression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anemia, Refractory, with Excess of Blasts / diagnosis
-
Anemia, Refractory, with Excess of Blasts / drug therapy
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Drug Administration Schedule
-
Enzyme Inhibitors / administration & dosage*
-
Enzyme Inhibitors / adverse effects
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Middle Aged
-
Myelodysplastic Syndromes / diagnosis
-
Myelodysplastic Syndromes / drug therapy*
-
Remission Induction
-
Topotecan / administration & dosage*
-
Topotecan / adverse effects
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Topotecan